ATE223424T1 - Quinazolinon-verbindungen - Google Patents

Quinazolinon-verbindungen

Info

Publication number
ATE223424T1
ATE223424T1 AT98902115T AT98902115T ATE223424T1 AT E223424 T1 ATE223424 T1 AT E223424T1 AT 98902115 T AT98902115 T AT 98902115T AT 98902115 T AT98902115 T AT 98902115T AT E223424 T1 ATE223424 T1 AT E223424T1
Authority
AT
Austria
Prior art keywords
phosphate
alkyl
optionally substituted
compounds
derivative
Prior art date
Application number
AT98902115T
Other languages
English (en)
Inventor
Roger John Griffin
Alan Hilary Calvert
Nicola Jane Curtin
David Richard Newell
Bernard Thomas Golding
Original Assignee
Univ Newcastle Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Newcastle Ventures Ltd filed Critical Univ Newcastle Ventures Ltd
Application granted granted Critical
Publication of ATE223424T1 publication Critical patent/ATE223424T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98902115T 1997-02-01 1998-01-30 Quinazolinon-verbindungen ATE223424T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9702701.5A GB9702701D0 (en) 1997-02-01 1997-02-01 Quinazolinone compounds
PCT/GB1998/000303 WO1998033802A1 (en) 1997-02-01 1998-01-30 Quinazolinone compounds

Publications (1)

Publication Number Publication Date
ATE223424T1 true ATE223424T1 (de) 2002-09-15

Family

ID=10807378

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98902115T ATE223424T1 (de) 1997-02-01 1998-01-30 Quinazolinon-verbindungen

Country Status (10)

Country Link
US (1) US6156739A (de)
EP (1) EP0966476B1 (de)
JP (1) JP2001511776A (de)
KR (1) KR20000070467A (de)
AT (1) ATE223424T1 (de)
AU (1) AU5873998A (de)
CA (1) CA2278290C (de)
DE (1) DE69807661D1 (de)
GB (1) GB9702701D0 (de)
WO (1) WO1998033802A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916460B4 (de) * 1999-04-12 2006-12-21 Abbott Gmbh & Co. Kg Substituierte Benzimidazole, deren Herstellung und Anwendung
NZ511825A (en) 1998-11-27 2003-08-29 Basf Ag Substituted benzimidazoles and their use as parp inhibitors
HRP20010573B1 (en) 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
AU2004200A (en) * 1999-01-14 2000-08-01 Meiji Seika Kaisha Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
PL358393A1 (en) * 2000-03-20 2004-08-09 N-Gene Research Laboratories Inc. Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
US20030105118A1 (en) * 2000-04-18 2003-06-05 Shuji Masumoto Tricyclic quinazolinediones
MXPA02010618A (es) * 2000-04-25 2004-05-05 Icos Corp Inhibidores de fosfatidilinositol 3-quinasa delta.
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US7514067B2 (en) 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
DE10034801A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Amidoalkyl-uracile und ihre Verwendung
WO2002044157A2 (en) * 2000-12-01 2002-06-06 Iconix Pharmaceuticals, Inc. Parb inhibitors
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
KR20030071029A (ko) * 2002-02-27 2003-09-03 주식회사 팜제니아 항암제 및 방사선 치료 증진제로서 유용한 조성물
CA2500952C (en) 2002-10-04 2011-04-26 Prana Biotechnology Limited Neurologically-active compounds
EP1582520A1 (de) * 2002-11-12 2005-10-05 Mochida Pharmaceutical Co., Ltd. Neue parp-inhibitoren
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1506967B1 (de) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl Peptidase Inhibitoren.
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1699777B1 (de) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidylpeptidase-hemmer
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06010571A (es) 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
PL1761540T3 (pl) 2004-05-13 2017-06-30 Icos Corporation Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EP1828192B1 (de) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidylpeptidasehemmer
EP2319847A3 (de) 2005-01-19 2012-06-20 Eisai Inc. Diazabenzo[de]anthracen-3-on-Verbindungen und Verfahren zur Hemmung von PARP
NZ565654A (en) 2005-07-18 2010-10-29 Bipar Sciences Inc Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
ME02005B (me) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibitori dipeptidil peptidaze za lečenje dijabetesa
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
US9150628B2 (en) 2005-11-14 2015-10-06 Centre National De La Recherche Scientifique (Cnrs) PARP inhibitors
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20100144693A1 (en) 2006-04-14 2010-06-10 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (amd)
ES2385849T3 (es) 2006-05-02 2012-08-01 Abbott Laboratories Las 1H-bencimidazol-4-carboxamidas substituidas son potentes inhibidores de la PARP
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
CA2662337A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
MY145447A (en) * 2006-09-13 2012-02-15 Takeda Pharmaceutical Use of 2-6(3-amino-piperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydrp-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
PL2209375T3 (pl) 2007-10-03 2014-12-31 Eisai Inc Związki, kompozycje i metody stosowania inhibitorów PARP
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
NZ631024A (en) 2008-11-13 2016-04-29 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
SG174529A1 (en) 2009-03-24 2011-10-28 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EP2456443A1 (de) 2009-07-21 2012-05-30 Gilead Calistoga LLC Behandlung von lebererkrankungen mit pi3k-hemmern
AU2011298423B2 (en) * 2010-09-03 2015-11-05 Bayer Intellectual Property Gmbh Substituted fused pyrimidinones and dihydropyrimidinones
WO2012071684A1 (en) 2010-12-02 2012-06-07 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivates，preparation processes and medical uses thereof
JP5831997B2 (ja) * 2011-02-15 2015-12-16 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ ３−アリールエチニル置換キナゾリノン化合物
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2855994A1 (en) * 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
AP2014007875A0 (en) 2012-03-05 2014-08-31 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
AU2013324681B2 (en) 2012-09-26 2017-08-10 Merck Patent Gmbh Quinazolinone derivatives as PARP inhibitors
WO2014087165A1 (en) * 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
WO2014098877A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
PT3083630T (pt) 2013-12-20 2019-11-15 Gilead Calistoga Llc Procedimentos para inibidores da fosfatidilinositol 3-quinase
EP3083623A1 (de) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphe formen eines hydrochloridsalzes aus (s)-2-(9h-purin-6-ylamino)propyl)-5-fluor-3-phenylchinazolin-4 (3h)-on
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
CN110300600A (zh) 2016-11-02 2019-10-01 伊缪诺金公司 利用抗体-药物缀合物和parp抑制剂的组合治疗
CN117229224A (zh) * 2022-06-07 2023-12-15 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024410A1 (en) * 1994-03-08 1995-09-14 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues

Also Published As

Publication number Publication date
AU5873998A (en) 1998-08-25
EP0966476A1 (de) 1999-12-29
DE69807661D1 (de) 2002-10-10
JP2001511776A (ja) 2001-08-14
US6156739A (en) 2000-12-05
CA2278290C (en) 2005-05-10
GB9702701D0 (en) 1997-04-02
WO1998033802A1 (en) 1998-08-06
CA2278290A1 (en) 1998-08-06
EP0966476B1 (de) 2002-09-04
KR20000070467A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
ATE223424T1 (de) Quinazolinon-verbindungen
GB9404485D0 (en) Benzamide analogues
MX9800577A (es) Derivados de 4,5-diaril oxazol.
ES2147836T3 (es) Derivados de 4,5-diariloxazol.
AU689304B2 (en) Quinazoline derivative
GEP20033001B (en) Alkynyl-Substituted Quinolin-2-One Derivatives Useful As Anticancer Agents
ES2149186T3 (es) Derivados de dihidrochalcona hipoglicemicos.
AUPR177300A0 (en) Therapeutic methods
GEP20032953B (en) Antitumor Agents
DE69506197D1 (de) Verwendung eines Ascorbyl-tocopherylphosphats zur Herstellung eines Arzneimittels zur Behandlung der Pankreatitis
DE69312567D1 (de) 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel
BR9506552A (pt) Método de inibição de integrase retroviral
WO1990014831A3 (en) 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
FR2700166B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
CA2228524A1 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating human malignancies
ZA939153B (en) Use of idazoxan and its derivatives for the preparation of a medicinal product intended for the treatment of parkinson's disease and its development
ZA961795B (en) Pharmaceuticals
ATE240329T1 (de) Zytotoxische pyrido(2,3,4-kl)acridinderivate, ihre herstellung und therapeutische verwendung
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
GB9323403D0 (en) Pharmaceuticals

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties